Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitous surface protein A2 (UspA2) is a major outer membrane protein of the Gram-negative bacterium Moraxella catarrhalis, which is a significant human respiratory pathogen. As a member of the trimeric autotransporter adhesin (TAA) family, UspA2 is essential for the bacterium's ability to adhere to human epithelial cells and survive in the host environment. One of its primary roles is providing serum resistance by binding to complement inhibitors like C4b-binding protein and vitronectin, effectively neutralizing the host's innate immune response. Because of its critical role in virulence and its presence in nearly all clinical isolates, UspA2 is a leading target for vaccine development aimed at preventing otitis media in children and exacerbations of chronic obstructive pulmonary disease (COPD) in adults. Current therapeutic efforts, such as those by GlaxoSmithKline, involve using recombinant UspA2 fragments to elicit protective, bactericidal antibodies (, NCT03318042). These vaccine candidates are designed to induce high titers of IgG that block bacterial attachment and facilitate clearance by the immune system. Despite its potential, challenges remain regarding the antigenic variation observed among different strains of M. catarrhalis.
Vaccine-induced production of neutralizing and bactericidal antibodies that block bacterial adhesion to host cells and inhibit complement evasion mechanisms.
1 more in the full profile.
Source types: Trial registry. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitous surface protein A2 (UspA2) (UspA2).